Articles tagged "FK506"

2015 American Transplant Congress
Phenotypic Personalized Medicine: Mechanism-Independent Convergence Into Target Serum Tacrolimus Levels for Optimized Liver Transplant Immunosuppression
A. Zarrinpar,¹ A. Silva,² D.-K. Lee,³ N. Datta,¹ C.-M. Ho,² D. Ho.³
¹Surgery-Division of Liver and Pancreas Transplantation, UCLA, Los Angeles, CA; ²Mechanical Engineering, UCLA, Los Angeles, CA; ³Bioengineering, and Oral Biology and Medicine, UCLA, Los Angeles, CA.
PURPOSE:Immunosuppressive drugs such as tacrolimus have narrow therapeutic ranges and their dosing variability necessitates intensive drug monitoring. This study aimed to use Feedback System Control…
2015 American Transplant Congress
Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing
T. Elnahhas,^1,2 E. de Jonge,⁴ T. Lee,² B. van Zelst,⁴ J. Popoola,³ R. Ramkhelawon,³ R. van Schaik,⁴ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom; ⁴Clinical Chemistry, Erasmus MC Rotterdam, Rotterdam, Netherlands.
Background—Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical practice (Diczfalusy et al, 2011). 4β-OHC concentration increases…
2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
T. Elnahhas,^1,2 T. Lee,² M. Moreton,² D. McKeown,² J. Popoola,³ R. Ramkhelawon,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St.George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St.George's University of London, London, United Kingdom.
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…
2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
T. Hsu,¹ J. Yin,¹ L. Awdishu,¹ J. Kerr,¹ R. Steiner.²
¹Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla; ²Medicine, UC San Diego School of Medicine, La Jolla.
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…